NEOT News

Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, postponed its IPO on Wednesday. The Boston, MA-based company was founded in 2006 and had planned to list on the NASDAQ under the symbol GLSS. Piper Jaffray, Stifel and Guggenheim Securities were set to be the joint bookrunners on the deal....read more

Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering. The company's lead candidate uses its proprietary hydrogel technology and is designed to work mechanically in the GI tract rather than act chemically through absorption in the blood stream....read more

9 companies went public in the past week as the IPO market raised $3.5 billion. At 26 deals, November issuance fell one IPO short of last year, unless CVSL manages to price next week. November IPOs raised $7.2 billion and averaged 19% from the offer price, including 4% after the first day. Two companies rose over 100% on their debut, the ...read more

Neothetics, which is developing an injectable version of an approved asthma drug to reduce belly fat, raised $65 million in an upsized IPO by offering 4.65 million shares (all primary) at $14, the midpoint of the range of $13 to $15. The company originally planned to offer 4.3 million shares. Neothetics plans to list on the NASDAQ under the symbol NEOT. Neothetics initially filed...read more